Personalised management of patients with hepatocellular carcinoma : a multiparametric therapeutic hierarchy concept
Copyright © 2023 Elsevier Ltd. All rights reserved..
Advances in the surgical and systemic therapeutic landscape of hepatocellular carcinoma have increased the complexity of patient management. A dynamic adaptation of the available staging-based algorithms is required to allow flexible therapeutic allocation. In particular, real-world hepatocellular carcinoma management increasingly relies on factors independent of oncological staging, including patients' frailty, comorbid burden, critical tumour location, multiple liver functional parameters, and specific technical contraindications impacting the delivery of treatment and resource availability. In this Policy Review we critically appraise how treatment allocation strictly based on pretreatment staging features has shifted towards a more personalised treatment approach, in which expert tumour boards assume a central role. We propose an evidence-based framework for hepatocellular carcinoma treatment based on the novel concept of multiparametric therapeutic hierarchy, in which different therapeutic options are ordered according to their survival benefit (ie, from surgery to systemic therapy). Moreover, we introduce the concept of converse therapeutic hierarchy, in which therapies are ordered according to their conversion abilities or adjuvant abilities (ie, from systemic therapy to surgery).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
The Lancet. Oncology - 24(2023), 7 vom: 06. Juli, Seite e312-e322 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vitale, Alessandro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 10.07.2023 Date Revised 20.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/S1470-2045(23)00186-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35915137X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35915137X | ||
| 003 | DE-627 | ||
| 005 | 20231227134732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(23)00186-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1233.xml |
| 035 | |a (DE-627)NLM35915137X | ||
| 035 | |a (NLM)37414020 | ||
| 035 | |a (PII)S1470-2045(23)00186-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vitale, Alessandro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Personalised management of patients with hepatocellular carcinoma |b a multiparametric therapeutic hierarchy concept |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.07.2023 | ||
| 500 | |a Date Revised 20.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Advances in the surgical and systemic therapeutic landscape of hepatocellular carcinoma have increased the complexity of patient management. A dynamic adaptation of the available staging-based algorithms is required to allow flexible therapeutic allocation. In particular, real-world hepatocellular carcinoma management increasingly relies on factors independent of oncological staging, including patients' frailty, comorbid burden, critical tumour location, multiple liver functional parameters, and specific technical contraindications impacting the delivery of treatment and resource availability. In this Policy Review we critically appraise how treatment allocation strictly based on pretreatment staging features has shifted towards a more personalised treatment approach, in which expert tumour boards assume a central role. We propose an evidence-based framework for hepatocellular carcinoma treatment based on the novel concept of multiparametric therapeutic hierarchy, in which different therapeutic options are ordered according to their survival benefit (ie, from surgery to systemic therapy). Moreover, we introduce the concept of converse therapeutic hierarchy, in which therapies are ordered according to their conversion abilities or adjuvant abilities (ie, from systemic therapy to surgery) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Cabibbo, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Iavarone, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Viganò, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Pinato, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Ponziani, Francesca Romana |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Quirino |e verfasserin |4 aut | |
| 700 | 1 | |a Casadei-Gardini, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Celsa, Ciro |e verfasserin |4 aut | |
| 700 | 1 | |a Galati, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Gambato, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Crocetti, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Renzulli, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Giannini, Edoardo G |e verfasserin |4 aut | |
| 700 | 1 | |a Farinati, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Trevisani, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Cillo, Umberto |e verfasserin |4 aut | |
| 700 | 0 | |a HCC Special Interest Group of the Italian Association for the Study of the Liver |e verfasserin |4 aut | |
| 700 | 1 | |a Baccarani, Umberto |e investigator |4 oth | |
| 700 | 1 | |a Brancaccio, Giuseppina |e investigator |4 oth | |
| 700 | 1 | |a Cozzolongo, Raffaele |e investigator |4 oth | |
| 700 | 1 | |a Cucchetti, Alessandro |e investigator |4 oth | |
| 700 | 1 | |a De Matthaeis, Nicoletta |e investigator |4 oth | |
| 700 | 1 | |a Di Sandro, Stefano |e investigator |4 oth | |
| 700 | 1 | |a Famularo, Simone |e investigator |4 oth | |
| 700 | 1 | |a Finotti, Michele |e investigator |4 oth | |
| 700 | 1 | |a Foschi, Francesco G |e investigator |4 oth | |
| 700 | 1 | |a Ghinolfi, Davide |e investigator |4 oth | |
| 700 | 1 | |a Guarracino, Marco |e investigator |4 oth | |
| 700 | 1 | |a Gruttadauria, Salvatore |e investigator |4 oth | |
| 700 | 1 | |a Guarino, Maria |e investigator |4 oth | |
| 700 | 1 | |a Kostandini, Alba |e investigator |4 oth | |
| 700 | 1 | |a Lenci, Ilaria |e investigator |4 oth | |
| 700 | 1 | |a Levi Sandri, Giovanni B |e investigator |4 oth | |
| 700 | 1 | |a Manzia, Tommaso M |e investigator |4 oth | |
| 700 | 1 | |a Marasco, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Masarone, Mario |e investigator |4 oth | |
| 700 | 1 | |a Mazzarelli, Chiara |e investigator |4 oth | |
| 700 | 1 | |a Melandro, Fabio |e investigator |4 oth | |
| 700 | 1 | |a Miele, Luca |e investigator |4 oth | |
| 700 | 1 | |a Morisco, Filomena |e investigator |4 oth | |
| 700 | 1 | |a Nicolini, Daniele |e investigator |4 oth | |
| 700 | 1 | |a Pagano, Duilio |e investigator |4 oth | |
| 700 | 1 | |a Pelizzaro, Filippo |e investigator |4 oth | |
| 700 | 1 | |a Pieri, Giulia |e investigator |4 oth | |
| 700 | 1 | |a Piscaglia, Fabio |e investigator |4 oth | |
| 700 | 1 | |a Plaz Torres, Maria Corina |e investigator |4 oth | |
| 700 | 1 | |a Pravisani, Riccardo |e investigator |4 oth | |
| 700 | 1 | |a Rendina, Maria |e investigator |4 oth | |
| 700 | 1 | |a Romano, Fabrizio |e investigator |4 oth | |
| 700 | 1 | |a Russo, Francesco P |e investigator |4 oth | |
| 700 | 1 | |a Sacco, Rodolfo |e investigator |4 oth | |
| 700 | 1 | |a Sangiovanni, Angelo |e investigator |4 oth | |
| 700 | 1 | |a Sposito, Carlo |e investigator |4 oth | |
| 700 | 1 | |a Tortora, Raffaella |e investigator |4 oth | |
| 700 | 1 | |a Tovoli, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Viganò, Mauro |e investigator |4 oth | |
| 700 | 1 | |a Violi, Paola |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Oncology |d 2000 |g 24(2023), 7 vom: 06. Juli, Seite e312-e322 |w (DE-627)NLM117859516 |x 1474-5488 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:7 |g day:06 |g month:07 |g pages:e312-e322 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1470-2045(23)00186-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 7 |b 06 |c 07 |h e312-e322 | ||